ORIGINAL RESEARCH article
Front. Genet.
Sec. Cancer Genetics and Oncogenomics
Clinical Significance and Oncogenic Role of ECHDC2 in Glioblastoma: A Comprehensive Analysis Based on Bioinformatics and In Vitro Experiments
Provisionally accepted
Shengliang Lin1
Tian Wei2
Qian Wu3Qingqing Liu3Longyun Hu3Bigui Song3Jiejing Lin3
ZeWei Zhao3Yi Cai3Xiaoxiao Li3
Zhonghan Yang3*Chengming Li4*Xiping Hu1*- 1Beijing Institute of Technology, Beijing, China
- 2Sun Yat-Sen University, Guangzhou, China
- 3Sun Yat-Sen University, Shenzhen, China
- 4Shenzhen MSU-BIT University, Shenzhen, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Growing evidence implicates enoyl-CoA hydratase domain-containing protein 2 (ECHDC2) in oncogenesis, yet its role in glioblastoma (GBM) remains undefined. We aimed to clarify the pathological significance and molecular mechanisms of ECHDC2 in GBM. Methods Gene-expression profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were analyzed. Kaplan–Meier curves were used to evaluate the prognostic value of ECHDC2. Immune cell infiltration was quantified using CIBERSORT, single-sample gene-set enrichment analysis (ssGSEA), and ESTIMATE algorithms. Spearman’s correlation analysis was applied to assess the associations between ECHDC2 expression levels, immune checkpoint molecules, and immune cell subsets. To elucidate the functional relevance of ECHDC2, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene-set enrichment analyses (GSEA) were performed, while protein-protein interaction (PPI) networks were investigated using the STRING database. Subsequently, ECHDC2 was knocked down or overexpressed in GBM cell lines, and its effects on cell proliferation and migration were determined using CCK-8, EdU, wound-healing, and Transwell migration assays. Results Upregulated ECHDC2 expression was significantly correlated with unfavorable clinicopathological features and reduced overall survival (OS) in patients with GBM. High ECHDC2 expression was associated with increased infiltration of effector-memory CD8⁺ T cells (TEM) and plasmacytoid dendritic cells (pDCs). Enrichment analyses demonstrated that ECHDC2 is involved in tumor progression, with a particular focus on the PI3K/Akt signaling pathway. In vitro experiments showed that ECHDC2 knockdown suppressed the proliferation and migration of GBM cells. Conversely, ECHDC2 overexpression exerted the opposite effects on GBM cell proliferation and migration. Conclusions ECHDC2 overexpression promotes GBM progression and portends poor prognosis. ECHDC2 may serve as both a prognostic biomarker and a therapeutic target in GBM
Keywords: bioinformatics, ECHDC2, Glioblastoma, Immune infiltration, PI3K/AKT
Received: 03 Dec 2025; Accepted: 20 Jan 2026.
Copyright: © 2026 Lin, Wei, Wu, Liu, Hu, Song, Lin, Zhao, Cai, Li, Yang, Li and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhonghan Yang
Chengming Li
Xiping Hu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.